این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Cell Journal، جلد ۱۶، شماره Suppl ۱، صفحات ۱۶۶-۱۶۶
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Ps-135: Hematopoietic Stem Cell Transplantation to Treat Multiple Sclerosis
چکیده انگلیسی مقاله Objective: Traditional therapies for MS (IFN-β and glatiramer acetate) have achieved modest therapeutic benefits for patients with less aggressive MS but rarely reducing or reversing pre-existing disabilities. Now, more potent agents that interfere with immune function (natalizumab, fingolimod and etc.) have shown better activity at suppressing MS relapses but do not significantly reverse disability. Thus, autologous hematopoietic stem cell transplantation (HSCT) is proposed as a treatment for MS based on favorable results in experimental autoimmune encephalomyelitis. Materials and Methods: This paper is a report of a review to evaluate the efficacy of HSCT in MS treatment and is prepared from 30 reputable articles. First,HSCT protocol is presented, and then efficacy and results of this therapy are discussed. Results: Since negligible HSCs are detectable in the peripheral blood, either a hematopoietic growth factor or chemotherapy is necessary to mobilize HSCs. HSCs are collected by apheresis. Blood is drawn from one lumen of the catheter, and mononuclear cells are separated by an external centrifuge and returned to the patient through the second catheter lumen. The PBSCs are further processed by immunoselection for a HSC phenotype and then cryopreserved. HSCs differentiate and replenish all types of blood cells. Conclusion: The leading indication for autologous HSCT of autoimmune diseases is MS and over 500 patients with MS have undergone this procedure. Clinical studies showed a decrease of disease progression in almost 70% of cases, at least in the first three years of follow- up, and a dramatic reduction of relapses. The MRI studies demonstrated that autologous HSCT has the capacity of a profound and long-lasting suppression of gadolinium-enhancing lesions. New active lesions were rarely detected. Furthermore, the MRI studies showed that the volume of brain atrophy decreased significantly with time after 2–3 years following autologous HSCT. Nowadays, HSCT considers as a form of intense immunosuppressive therapy.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله
نشانی اینترنتی http://celljournal.org/journal/article/abstract/460
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات